Chronic Fatigue Syndrome (ME/CFS) Treatment
Chronic fatigue syndrome (ME/CFS) treatment at The Neurogenesis Project starts from what the research now shows: myalgic encephalomyelitis has measurable neuroinflammatory, autonomic, and metabolic signatures. For decades it was dismissed as psychosomatic, a diagnosis of exclusion handed to patients whose labs come back clean and whose MRI looks normal. The problem isn’t that nothing is wrong. The problem is that the standard workup wasn’t designed to find it.
Available at our St. Marys, Georgia clinic.
The Neurology of ME/CFS
ME/CFS is not fatigue. Fatigue is a symptom. ME/CFS is a multisystem neuroimmune disease with documented pathology in the brain, the autonomic nervous system, and cellular energy metabolism. The distinction matters because it determines whether patients receive treatment that addresses root mechanisms or are simply told to rest and manage their expectations.
In 2014, Nakatomi et al. published a landmark PET imaging study in Brain demonstrating widespread neuroinflammation in ME/CFS patients. Using the radiotracer 11C-(R)-PK11195, which binds to activated microglia, the researchers found elevated neuroinflammation in the cingulate cortex, hippocampus, amygdala, thalamus, midbrain, and pons. The degree of neuroinflammation correlated with the severity of cognitive symptoms. This was not subjective reporting. It was visible on a brain scan.
VanElzakker proposed the vagus nerve infection hypothesis in 2013, arguing that low-level infection or immune activation along the vagus nerve could generate the sickness behavior signals—fatigue, cognitive impairment, pain sensitivity, malaise—that define ME/CFS. Because the vagus nerve is the primary conduit between peripheral immune signals and the brainstem, even subclinical viral persistence along this pathway could produce the full clinical picture without a detectable systemic infection.
The metabolic dimension is equally striking. Fluge and Mella at Haukeland University Hospital in Bergen identified impaired pyruvate dehydrogenase function in ME/CFS patients—a bottleneck at the entry point of the mitochondrial energy cycle that forces cells toward inefficient anaerobic metabolism. Their work, along with findings from Robert Naviaux at UC San Diego showing a hypometabolic state resembling dauer in ME/CFS, points to a fundamental disruption in how cells produce energy. When neurons cannot generate adequate ATP, cognition slows, fatigue deepens, and post-exertional malaise becomes inevitable.
In 2015, the Institute of Medicine formally recognized the severity of ME/CFS by proposing the name Systemic Exertion Intolerance Disease (SEID) and establishing diagnostic criteria centered on post-exertional malaise, unrefreshing sleep, and cognitive or orthostatic impairment. The report estimated that 836,000 to 2.5 million Americans were affected and that the majority remained undiagnosed.
Not Depression. Not Deconditioning.
One of the most damaging patterns in ME/CFS care is the reflexive misattribution to depression. Both conditions involve fatigue, cognitive difficulty, and sleep disruption. But the overlap in symptoms masks a fundamental difference in mechanism—and conflating the two leads to treatment that actively harms ME/CFS patients.
The distinguishing feature is post-exertional malaise (PEM). A patient with major depression who exercises may feel temporarily better. A patient with ME/CFS who exercises beyond their energy envelope crashes 12 to 72 hours later with worsened fatigue, cognitive dysfunction, pain, and sometimes fever or lymph node tenderness. Two-day cardiopulmonary exercise testing (CPET) has demonstrated this objectively: ME/CFS patients show a measurable decline in VO2 max and anaerobic threshold on the second test day that healthy controls and depressed patients do not.
Beyond PEM, ME/CFS patients frequently present with orthostatic intolerance—a drop in blood pressure or spike in heart rate upon standing that causes dizziness, presyncope, or frank syncope. Tilt table testing documents this in a majority of ME/CFS patients. Natural killer cell dysfunction, measured by reduced cytotoxic activity, is another objective finding that appears consistently in the ME/CFS literature and has no parallel in primary depression.
Graded exercise therapy (GET), once the standard recommendation for ME/CFS, was largely abandoned after patient surveys and re-analyses of the PACE trial demonstrated that it worsened outcomes for a substantial proportion of patients. The 2021 NICE guidelines in the United Kingdom formally reversed the recommendation. This reversal reflects what the biology has shown all along: ME/CFS is not deconditioning, and pushing through it does not build capacity. It deepens the metabolic deficit.
The Long COVID Overlap
The COVID-19 pandemic created millions of new ME/CFS patients almost overnight. Studies estimate that approximately half of long COVID patients meet the diagnostic criteria for ME/CFS, and the shared mechanisms are not coincidental—they are mechanistically identical.
Both conditions feature neuroinflammation with activated microglia, mitochondrial dysfunction with impaired ATP synthesis, autonomic dysregulation with measurable orthostatic intolerance, and immune activation with elevated inflammatory cytokines and complement markers. The trigger differs—ME/CFS can follow Epstein-Barr virus, enteroviruses, or other infections, while long COVID follows SARS-CoV-2—but the downstream pathology converges.
This convergence has practical implications for treatment. A patient who developed post-exertional malaise, brain fog, and orthostatic intolerance after COVID in 2020 and a patient who developed the same constellation after mononucleosis in 2015 are not different diseases requiring different approaches. They are the same broken machinery driven by different initial insults. At The Neurogenesis Project, we treat the mechanisms we find regardless of the original trigger.
Our Treatment Protocol for ME/CFS
Once diagnostics identify the specific mechanisms at work, we build a protocol from therapies that target neuroinflammation, mitochondrial recovery, autonomic stabilization, and immune modulation. No two ME/CFS patients present identically, and no two protocols should be either.
Exosome Therapy
Extracellular vesicles that cross the blood-brain barrier and deliver anti-inflammatory signals directly to reactive microglia. Exosomes carry cytokines, growth factors, and regulatory microRNAs that modulate the neuroinflammatory cascade sustaining ME/CFS and support repair of blood-brain barrier integrity.
NAD+ IV Therapy
ME/CFS depletes NAD+ through chronic immune activation and mitochondrial stress. IV NAD+ restores the central coenzyme in the electron transport chain, directly addressing the impaired pyruvate dehydrogenase function and ATP deficit that drive post-exertional malaise, cognitive slowing, and the deep fatigue of ME/CFS.
Stem Cell Therapy
Mesenchymal stem cells modulate the dysregulated immune response that sustains chronic neuroinflammation in ME/CFS. These cells home to areas of immune activation and release trophic factors that promote vascular repair, reduce complement activation, and support restoration of autonomic balance.
Glutathione IV Therapy
The brain’s primary endogenous antioxidant. IV glutathione neutralizes the reactive oxygen species generated by sustained microglial activation and mitochondrial dysfunction, reducing oxidative damage to neurons and supporting the cellular detoxification pathways that ME/CFS disrupts.
These therapies are delivered together during our Cellular Rejuvenation Program, an immersive protocol that combines diagnostics, physician review, and a full course of treatment in a single visit.
Our Diagnostic Approach
Every ME/CFS patient at The Neurogenesis Project begins with a diagnostic evaluation designed to identify the specific mechanisms sustaining their illness. We do not treat empirically. We measure first and build the protocol around what the data shows.
Advanced Neuroimaging. Functional imaging maps regional brain metabolism and network connectivity. In ME/CFS patients, this frequently reveals areas of hypometabolism in prefrontal and temporal regions consistent with the neuroinflammatory patterns documented by Nakatomi and colleagues. These findings guide the selection and intensity of anti-inflammatory therapies.
Inflammatory Biomarker Panels. We measure inflammatory cytokines (IL-6, TNF-alpha, IL-1beta), complement components (C3a, C5a), markers of endothelial activation, and indices of oxidative stress. These labs distinguish patients with active neuroinflammation from those whose symptoms are driven primarily by mitochondrial dysfunction, autonomic dysregulation, or a combination of mechanisms.
Mitochondrial Function Markers. Organic acid testing, lactate-to-pyruvate ratios, and related metabolic panels assess whether cellular energy production is impaired. In ME/CFS patients, these markers frequently confirm the mitochondrial bottleneck that Fluge, Mella, and Naviaux described—providing objective evidence for NAD+ and metabolic support therapies.
Autonomic Function Testing. Heart rate variability analysis, tilt table evaluation, and continuous cardiovascular monitoring quantify the autonomic instability that most ME/CFS patients experience as orthostatic intolerance, exercise intolerance, and erratic heart rate responses. These findings shape dosing strategy and determine whether autonomic-targeted interventions are included in the protocol.
Quantitative Cognitive Assessment. Standardized neuropsychological measures document processing speed, working memory capacity, verbal fluency, and executive function at baseline. These scores give us an objective benchmark against which to track recovery. Subjective reports of brain fog are real, but quantified data tells us exactly what is impaired and by how much.
Related Treatments
NAD+ IV Therapy
Restore mitochondrial energy production in neurons operating under metabolic stress. NAD+ is the primary substrate for ATP synthesis and a key regulator of sirtuins and DNA repair enzymes critical to recovery from chronic neuroimmune disease.
Exosome Therapy
Extracellular vesicles that cross the blood-brain barrier and deliver anti-inflammatory signals, growth factors, and regulatory microRNAs to neural tissue affected by chronic neuroinflammation.
Long COVID Brain Fog
Advanced diagnostics and treatment for post-COVID neurological symptoms including cognitive dysfunction, fatigue, autonomic instability, and persistent neuroinflammation that standard workups miss.
What to Expect
Comprehensive symptom history
Estimated time: 30 minutes
Dr. Orr takes a detailed history of your fatigue onset, post-exertional malaise triggers, cognitive symptoms, sleep quality, orthostatic intolerance, pain, and functional limitations. He reviews how many providers you have seen and what workups have already been done.
Neurological and autonomic examination
Estimated time: 20 minutes
A focused exam evaluates cognitive function, autonomic nervous system performance including orthostatic vital signs, reflexes, and neurological signs. Autonomic dysregulation is common in ME/CFS and is directly addressable with treatment.
Metabolic and immune workup
Estimated time: 30 minutes
Blood work targets mitochondrial function markers, inflammatory cytokines, immune cell panels, hormone levels, and metabolic parameters. These tests look for the biological underpinnings of the fatigue that standard medical workups often fail to assess.
Brain imaging and functional assessment
Estimated time: 30 minutes
Brain MRI and neurocognitive testing evaluate for neuroinflammation, structural changes, and cortical dysfunction patterns that correlate with cognitive and fatigue symptoms.
Individualized treatment protocol
Estimated time: 30 minutes
Treatment may include IV NAD+ and glutathione for mitochondrial support, autonomic rehabilitation, pacing strategies, and targeted interventions for any specific immune or metabolic abnormalities identified. Dr. Orr tracks response with repeat testing.
Frequently Asked Questions
How do you distinguish ME/CFS from depression or deconditioning?+
The key difference is post-exertional malaise: ME/CFS patients get significantly worse 12 to 72 hours after activity that would not affect a healthy person. Depression causes low motivation but not this delayed physical crash. We also check for specific immune and inflammatory markers.
Read the full answer
The hallmark of ME/CFS is post-exertional malaise: a measurable worsening of symptoms 12 to 72 hours after physical or cognitive exertion that would not affect a healthy person. Depression causes low motivation and anhedonia, but it does not produce the delayed physiological crash that ME/CFS patients experience. Deconditioning improves with graded activity; ME/CFS worsens with it. We also look for orthostatic intolerance, natural killer cell dysfunction, and inflammatory biomarker patterns that are absent in primary mood disorders. When these objective findings are present, the diagnosis is neurological, not psychiatric.
What diagnostic tests do you use for ME/CFS?+
We go beyond standard blood work with advanced brain imaging, inflammatory biomarker panels, autonomic function testing, mitochondrial markers, and cognitive assessment. These tests show which specific mechanisms are driving your symptoms.
Read the full answer
We begin with a comprehensive evaluation that goes well beyond standard blood work. Our workup includes advanced neuroimaging to assess brain metabolism and connectivity, inflammatory biomarker panels measuring cytokines, complement activation, and oxidative stress markers, autonomic function testing including tilt table evaluation and heart rate variability analysis, mitochondrial function markers, and standardized neurocognitive assessment. Together, these tests identify which mechanisms are driving each patient's symptoms so we can build a targeted protocol rather than guessing.
Is ME/CFS related to long COVID?+
Yes. Many post-COVID patients meet the diagnostic criteria for ME/CFS, and the underlying problems are similar: brain inflammation, energy production failure, and immune activation. We treat the mechanisms we find regardless of what triggered them.
Read the full answer
There is substantial overlap. Many patients who develop persistent symptoms after SARS-CoV-2 infection meet the diagnostic criteria for ME/CFS, and the underlying mechanisms are remarkably similar: neuroinflammation, mitochondrial dysfunction, autonomic dysregulation, and immune activation. The IOM estimated in 2015 that 836,000 to 2.5 million Americans had ME/CFS. Post-COVID, those numbers have likely grown significantly. Regardless of the trigger, we treat the mechanisms we find rather than the label attached to them.
Does insurance cover ME/CFS treatment at your clinic?+
No. We operate outside insurance networks but provide documentation for potential out-of-network reimbursement. Our coordinator can discuss costs and payment options before you schedule.
Read the full answer
The Neurogenesis Project operates outside of insurance networks. Our diagnostic and treatment protocols use advanced therapies that are not typically covered by commercial insurance plans or Medicare. We provide detailed superbills and medical documentation that patients can submit to their carriers for potential out-of-network reimbursement. Our patient coordinator can discuss costs, payment plans, and documentation options before you schedule.
How long does the treatment program take?+
The initial program runs three to five consecutive days. Some patients return for follow-up infusions every four to eight weeks. Most patients notice improvement within two to four weeks.
Read the full answer
Our Intensive Brain Health Program is typically delivered over three to five consecutive days. Patients receive diagnostic testing, a detailed review of findings with Dr. Orr, and a full course of IV-based and regenerative therapies during that window. Some patients return for follow-up infusion cycles at intervals of four to eight weeks depending on their response. Most patients report measurable improvement within two to four weeks of completing the initial program.
I have been sick for years. Is it too late for treatment to help?+
No. We treat patients who have been sick for ten years or longer. The underlying problems often persist, which means they are still present on testing and still treatable. How long you have been sick affects the pace of recovery, not whether recovery is possible.
Read the full answer
No. We see patients who have been symptomatic for a decade or longer. The neuroinflammatory and metabolic pathology driving ME/CFS does not always resolve on its own, but that also means it is still present and still treatable. Patients with long disease duration often show measurable abnormalities on advanced diagnostics, which means there is still something to target. Duration of illness affects the pace of recovery, but it does not determine whether recovery is possible.
Can graded exercise therapy make ME/CFS worse?+
Yes, it can. Post-exertional malaise means activity beyond your limits triggers a crash lasting days to weeks. Updated medical guidelines no longer recommend graded exercise for ME/CFS. We focus on pacing and treating the underlying metabolic and inflammatory problems.
Read the full answer
It can. Post-exertional malaise is the hallmark feature of ME/CFS, meaning exertion beyond the patient's energy envelope triggers disproportionate symptom worsening lasting days to weeks. The 2021 NICE guidelines explicitly removed graded exercise therapy as a recommended treatment based on patient evidence of harm. We do not prescribe it. Activity management and pacing are safer while we address the underlying metabolic and inflammatory contributors.
Do you test for co-existing conditions like POTS, mast cell activation, or small fiber neuropathy?+
Yes. We screen for POTS with standing tests, mast cell activation through blood and urine markers, and small fiber neuropathy through skin biopsy. Finding these conditions changes the treatment plan.
Read the full answer
Yes. We screen for POTS with active standing testing. Mast cell activation is evaluated through tryptase levels and urine prostaglandin and histamine metabolites. Small fiber neuropathy is identified through skin punch biopsy measuring epidermal nerve fiber density. Identifying these co-existing conditions changes the treatment plan in ways the primary ME/CFS diagnosis alone would not explain.
Can IV therapies like NAD+ or Myers' Cocktail help with ME/CFS?+
When lab work shows mitochondrial dysfunction, NAD+ IV directly addresses the energy production deficit. The Myers' Cocktail provides magnesium and B vitamins at levels that bypass impaired gut absorption. These are targeted metabolic supports, not cure-alls.
Read the full answer
When lab work demonstrates mitochondrial dysfunction, IV NAD+ directly addresses the cofactor deficit impairing cellular energy production. The Myers' Cocktail provides magnesium and B vitamins at concentrations that bypass impaired gut absorption. These are metabolic support interventions that, in the right patient, can improve energy production. They are not curative, and we do not present them as such.
Your Fatigue Deserves a Real Diagnosis
If you’ve been told your labs are normal and your fatigue is just stress, depression, or deconditioning—but you know something is wrong because exertion makes you worse, not better—that disconnect between what the tests show and what your body tells you is exactly where we work. Dr. Orr and the team at The Neurogenesis Project are accepting new ME/CFS patients in St. Marys, Georgia.